166 related articles for article (PubMed ID: 21052089)
1. A phase-2 trial of low-dose pomalidomide in myelofibrosis.
Begna KH; Mesa RA; Pardanani A; Hogan WJ; Litzow MR; McClure RF; Tefferi A
Leukemia; 2011 Feb; 25(2):301-4. PubMed ID: 21052089
[TBL] [Abstract][Full Text] [Related]
2. Circulating levels of MCP-1, sIL-2R, IL-15, and IL-8 predict anemia response to pomalidomide therapy in myelofibrosis.
Pardanani A; Begna K; Finke C; Lasho T; Tefferi A
Am J Hematol; 2011 Apr; 86(4):343-5. PubMed ID: 21442636
[TBL] [Abstract][Full Text] [Related]
3. Long-term outcome of pomalidomide therapy in myelofibrosis.
Begna KH; Pardanani A; Mesa R; Litzow MR; Hogan WJ; Hanson CA; Tefferi A
Am J Hematol; 2012 Jan; 87(1):66-8. PubMed ID: 22081489
[TBL] [Abstract][Full Text] [Related]
4. Pomalidomide is active in the treatment of anemia associated with myelofibrosis.
Tefferi A; Verstovsek S; Barosi G; Passamonti F; Roboz GJ; Gisslinger H; Paquette RL; Cervantes F; Rivera CE; Deeg HJ; Thiele J; Kvasnicka HM; Vardiman JW; Zhang Y; Bekele BN; Mesa RA; Gale RP; Kantarjian HM
J Clin Oncol; 2009 Sep; 27(27):4563-9. PubMed ID: 19652059
[TBL] [Abstract][Full Text] [Related]
5. Phase II study of pomalidomide in combination with prednisone in patients with myelofibrosis and significant anemia.
Daver N; Shastri A; Kadia T; Newberry K; Pemmaraju N; Jabbour E; Zhou L; Pierce S; Cortes J; Kantarjian H; Verstovsek S
Leuk Res; 2014 Sep; 38(9):1126-9. PubMed ID: 25047979
[TBL] [Abstract][Full Text] [Related]
6. Phase1/-2 study of Pomalidomide in myelofibrosis.
Mesa RA; Pardanani AD; Hussein K; Wu W; Schwager S; Litzow MR; Hogan WJ; Tefferi A
Am J Hematol; 2010 Feb; 85(2):129-30. PubMed ID: 20052748
[No Abstract] [Full Text] [Related]
7. Low-dose thalidomide ameliorates cytopenias and splenomegaly in myelofibrosis with myeloid metaplasia: a phase II trial.
Marchetti M; Barosi G; Balestri F; Viarengo G; Gentili S; Barulli S; Demory JL; Ilariucci F; Volpe A; Bordessoule D; Grossi A; Le Bousse-Kerdiles MC; Caenazzo A; Pecci A; Falcone A; Broccia G; Bendotti C; Bauduer F; Buccisano F; Dupriez B
J Clin Oncol; 2004 Feb; 22(3):424-31. PubMed ID: 14752066
[TBL] [Abstract][Full Text] [Related]
8. Modest activity of pomalidomide in patients with myelofibrosis and significant anemia.
Daver N; Shastri A; Kadia T; Quintas-Cardama A; Jabbour E; Konopleva M; O'Brien S; Pierce S; Zhou L; Cortes J; Kantarjian H; Verstovsek S
Leuk Res; 2013 Nov; 37(11):1440-4. PubMed ID: 23890523
[TBL] [Abstract][Full Text] [Related]
9. [Transfusion independence achieved with pomalidomide therapy in a patient with primary myelofibrosis].
Edahiro Y; Gotoh A; Inano T; Tsutsui M; Tsukune Y; Yasuda H; Komatsu N
Rinsho Ketsueki; 2018; 59(3):323-325. PubMed ID: 29618692
[TBL] [Abstract][Full Text] [Related]
10. Lenalidomide plus prednisone results in durable clinical, histopathologic, and molecular responses in patients with myelofibrosis.
Quintás-Cardama A; Kantarjian HM; Manshouri T; Thomas D; Cortes J; Ravandi F; Garcia-Manero G; Ferrajoli A; Bueso-Ramos C; Verstovsek S
J Clin Oncol; 2009 Oct; 27(28):4760-6. PubMed ID: 19720904
[TBL] [Abstract][Full Text] [Related]
11. Phase I trial of pomalidomide given for patients with advanced solid tumors.
Cooney MM; Nock C; Bokar J; Krishnamurthi S; Gibbons J; Rodal MB; Ness A; Remick SC; Dreicer R; Dowlati A
Cancer Chemother Pharmacol; 2012 Nov; 70(5):755-61. PubMed ID: 22875080
[TBL] [Abstract][Full Text] [Related]
12. The presence of JAK2V617F in primary myelofibrosis or its allele burden in polycythemia vera predicts chemosensitivity to hydroxyurea.
Sirhan S; Lasho TL; Hanson CA; Mesa RA; Pardanani A; Tefferi A
Am J Hematol; 2008 May; 83(5):363-5. PubMed ID: 18266209
[TBL] [Abstract][Full Text] [Related]
13. A randomized study of pomalidomide vs placebo in persons with myeloproliferative neoplasm-associated myelofibrosis and RBC-transfusion dependence.
Tefferi A; Al-Ali HK; Barosi G; Devos T; Gisslinger H; Jiang Q; Kiladjian JJ; Mesa R; Passamonti F; McMullin MF; Ribrag V; Schiller G; Vannucchi AM; Zhou D; Reiser D; Zhong J; Gale RP
Leukemia; 2017 Apr; 31(4):896-902. PubMed ID: 27773929
[TBL] [Abstract][Full Text] [Related]
14. Thalidomide therapy for myelofibrosis with myeloid metaplasia.
Thomas DA; Giles FJ; Albitar M; Cortes JE; Verstovsek S; Faderl S; O'Brien SM; Garcia-Manero G; Keating MJ; Pierce S; Zeldis J; Kantarjian HM
Cancer; 2006 May; 106(9):1974-84. PubMed ID: 16583431
[TBL] [Abstract][Full Text] [Related]
15. Improvement of the hematologic toxicities of ruxolitinib in patients with MPN-associated myelofibrosis using a combination of thalidomide, stanozolol and prednisone.
Duan M; Zhou D
Hematology; 2019 Dec; 24(1):516-520. PubMed ID: 31242816
[No Abstract] [Full Text] [Related]
16. Lenalidomide therapy in myelofibrosis with myeloid metaplasia.
Tefferi A; Cortes J; Verstovsek S; Mesa RA; Thomas D; Lasho TL; Hogan WJ; Litzow MR; Allred JB; Jones D; Byrne C; Zeldis JB; Ketterling RP; McClure RF; Giles F; Kantarjian HM
Blood; 2006 Aug; 108(4):1158-64. PubMed ID: 16609064
[TBL] [Abstract][Full Text] [Related]
17. Danazol therapy for the anemia of myelofibrosis: assessment of efficacy with current criteria of response and long-term results.
Cervantes F; Isola IM; Alvarez-Larrán A; Hernández-Boluda JC; Correa JG; Pereira A
Ann Hematol; 2015 Nov; 94(11):1791-6. PubMed ID: 26122869
[TBL] [Abstract][Full Text] [Related]
18. International working group for myelofibrosis research and treatment response assessment and long-term follow-up of 50 myelofibrosis patients treated with thalidomide-prednisone based regimens.
Thapaliya P; Tefferi A; Pardanani A; Steensma DP; Camoriano J; Wu W; Geyer S; Mesa RA
Am J Hematol; 2011 Jan; 86(1):96-8. PubMed ID: 21132732
[TBL] [Abstract][Full Text] [Related]
19. [Comparison of low-dose thalidomide and prednisone combined with or without danazol for the treatment of primary myelofibrosis-associated anemia].
Xu J; Xu Z; Qin T; Li B; Fang L; Zhang H; Hu N; Pan L; Qu S; Zhang Y; Xiao Z
Zhonghua Xue Ye Xue Za Zhi; 2014 Aug; 35(8):698-702. PubMed ID: 25152115
[TBL] [Abstract][Full Text] [Related]
20. Therapeutic approaches in myelofibrosis.
Barosi G; Rosti V; Vannucchi AM
Expert Opin Pharmacother; 2011 Jul; 12(10):1597-611. PubMed ID: 21457082
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
